Verrica Pharmaceuticals (VRCA) Operating Expenses (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Operating Expenses of $14.7 million for Q1 2026, up 27.39% year-over-year from $11.6 million in Q1 2025, and up 19.98% quarter-over-quarter from $12.3 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Operating Expenses (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Operating Expenses history runs 10 years deep, the most recent figure standing at $14.7 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 27.39% year-over-year to $14.7 million; the TTM figure through Mar 2026 stood at $50.9 million (down 18.68% YoY), while the FY2025 annual figure was $47.8 million, down 35.0% from the prior year.
- Operating Expenses for Q1 2026 stood at $14.7 million, up from $12.3 million in the prior quarter.
- The five-year high for Operating Expenses was $26.8 million in Q3 2023, with the low at $6.3 million in Q4 2022.
- The 5-year median for Operating Expenses is $11.8 million (2023), against an average of $14.0 million.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses jumped 300.13% in 2023, then plunged 53.22% in 2024.
- Verrica Pharmaceuticals' Operating Expenses stood at $6.3 million in 2022, then surged by 300.13% to $25.1 million in 2023, then sank by 53.22% to $11.8 million in 2024, then increased by 4.51% to $12.3 million in 2025, then gained by 19.98% to $14.7 million in 2026.
- Business Quant data shows VRCA's Operating Expenses at $14.7 million in Q1 2026, $12.3 million in Q4 2025, and $12.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Verrica Pharmaceuticals | 104.71 Mn | 93.51 Mn | - | 18.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.96 Mn |
| Mar 31, 2026 | 14.74 Mn |
| Dec 31, 2025 | 12.28 Mn |
| Sep 30, 2025 | 12.72 Mn |
| Jun 30, 2025 | 11.19 Mn |
| Mar 31, 2025 | 11.57 Mn |
| Dec 31, 2024 | 11.75 Mn |
| Sep 30, 2024 | 18.92 Mn |
| Jun 30, 2024 | 20.38 Mn |
| Mar 31, 2024 | 22.43 Mn |
| Dec 31, 2023 | 25.12 Mn |
| Sep 30, 2023 | 26.83 Mn |
| Jun 30, 2023 | 11.80 Mn |
| Mar 31, 2023 | 7.13 Mn |
| Dec 31, 2022 | 6.28 Mn |
| Sep 30, 2022 | 6.87 Mn |
| Jun 30, 2022 | 9.34 Mn |
| Mar 31, 2022 | 7.84 Mn |
| Dec 31, 2021 | 8.47 Mn |
| Sep 30, 2021 | 11.77 Mn |